WEBULL
WebtradeDownload

Viking Therapeutics (VKTX) Stock Looks Fully Priced Despite Its Huge Five Year Run

Simply Wall St · 2d ago

Viking Therapeutics has been on a powerful multi year run, which puts fresh attention on a simple question for anyone looking at the stock today. Is the current share price still in step with the company’s book value, or has the recent enthusiasm pulled the market a long way from the balance sheet?

  • Over the past 5 years the stock has delivered a very large gain for early holders, which raises the stakes for anyone now asking how much of that success is already reflected in the valuation.
  • Positive trial data for VK2735 and other pipeline assets may support higher expectations for future revenue and cash generation, which in turn can change how much weight investors put on book value when they think about today’s price.
  • The analysts covering Viking Therapeutics have run their own numbers. See what analysts think Viking Therapeutics's shares could be worth.

The issue now is whether Viking Therapeutics’ share price around US$36.75 is well aligned with what investors are paying for on its balance sheet in terms of book value.

If you are weighing Viking Therapeutics against other ideas built around balance sheets and fundamentals, it can help to line it up next to companies from the solid balance sheet and fundamentals stocks screener (23 results).

Has Viking Therapeutics Run Too Far on Book Value?

P/B is usually a better starting lens for Viking Therapeutics than P/E, because the business is still loss making and has no meaningful earnings base yet.

On this measure, the share price trades at about 10.5x book value, using the P/B ratio of 10.499184x. The broader Biotechs group sits closer to 2.1x, while peers on average are around 4.3x, so the stock changes hands at a much richer level than both the sector and similar companies. The recent surge after the VK2735 weight loss maintenance data helps explain why, because enthusiasm for the pipeline means investors may be willing to pay a large premium to the current equity on the balance sheet.

That kind of gap usually signals that the market is banking on strong outcomes from Viking Therapeutics’ trials and future commercialisation, rather than on what the present net assets alone justify. It also means small setbacks can matter more to the valuation, because a high P/B leaves less room for disappointment. Explore the numbers behind Viking Therapeutics's P/B valuation.

NasdaqCM:VKTX P/B Ratio as at Sep 2026
NasdaqCM:VKTX P/B Ratio as at Sep 2026

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Viking Therapeutics' rich P/B multiple raises a simple follow up question for you as a holder or potential buyer. Simply Wall St Narratives pick that puzzle up and spell out which broad paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today’s quote, with each scenario tying its number to a concrete view of how the business might develop and the risks that could reshape that view over time on the Community page.

One of the top community narratives on Viking Therapeutics: 71% undervalued

"The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path…"

Discover why this Narrative puts Viking Therapeutics at 71% undervalued.

One more Viking Therapeutics check that belongs beside the valuation work

Before closing the file on Viking Therapeutics, it is worth asking who is actually steering the ship, how their rewards are structured, and whether those incentives align with the risks you are weighing. See who runs Viking Therapeutics and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.